255 related articles for article (PubMed ID: 31606057)
1. [Not Available].
Mosbah H; Brue T; Chanson P
Ann Endocrinol (Paris); 2019 Sep; 80 Suppl 1():S10-S18. PubMed ID: 31606057
[TBL] [Abstract][Full Text] [Related]
2. Pituitary tumours: acromegaly.
Chanson P; Salenave S; Kamenicky P; Cazabat L; Young J
Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
[TBL] [Abstract][Full Text] [Related]
3. [Current diagnosis and treatment of acromegaly].
Melgar V; Espinosa E; Cuenca D; Valle V; Mercado M
Rev Med Inst Mex Seguro Soc; 2015; 53(1):74-83. PubMed ID: 25680646
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly, a pituitary special issue.
Fleseriu M; Gadelha M
Pituitary; 2017 Feb; 20(1):2-3. PubMed ID: 28255899
[No Abstract] [Full Text] [Related]
6. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
7. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
8. LIMITATIONS OF CURRENT APPROACHES FOR THE TREATMENT OF ACROMEGALY.
Shanik MH
Endocr Pract; 2016 Feb; 22(2):210-9. PubMed ID: 26437214
[TBL] [Abstract][Full Text] [Related]
9. Growth Hormone Excess: Implications and Management.
Dhaneshwar S; Shandily S; Tiwari V
Endocr Metab Immune Disord Drug Targets; 2023; 23(6):748-763. PubMed ID: 36237164
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
11. Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study.
Pelsma ICM; Biermasz NR; Pereira AM; van Furth WR; Appelman-Dijkstra NM; Kloppenburg M; Kroon HM; Claessen KMJA
Eur J Endocrinol; 2020 Oct; 183(4):427-437. PubMed ID: 32688336
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly.
Chanson P; Salenave S; Kamenicky P
Handb Clin Neurol; 2014; 124():197-219. PubMed ID: 25248589
[TBL] [Abstract][Full Text] [Related]
14. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study.
Varadhan L; Reulen RC; Brown M; Clayton RN
Pituitary; 2016 Jun; 19(3):251-61. PubMed ID: 26724807
[TBL] [Abstract][Full Text] [Related]
15. Acromegaly: Update on Management and Long-Term Morbidities.
Kasuki L; Antunes X; Lamback EB; Gadelha MR
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):475-486. PubMed ID: 32741483
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
17. Absence of immunostaining for growth hormone in a subset of patients with acromegaly.
Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ
Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513
[TBL] [Abstract][Full Text] [Related]
18. The place of medical treatment of acromegaly: current status and perspectives.
Jallad RS; Bronstein MD
Expert Opin Pharmacother; 2013 Jun; 14(8):1001-15. PubMed ID: 23600991
[TBL] [Abstract][Full Text] [Related]
19. Treatment of persistent and recurrent acromegaly.
Del Porto LA; Liubinas SV; Kaye AH
J Clin Neurosci; 2011 Feb; 18(2):181-90. PubMed ID: 21167718
[TBL] [Abstract][Full Text] [Related]
20. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
